EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing
04-11-2019
servickuz / shutterstock.com
The first day of a landmark hearing on CRISPR ownership dealt nearly exclusively with untangling linguistic arguments, lawyers following the proceedings told LSIPR.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
CRISPR, CRISPR/Cas9, European Patent Office, EPO, Broad Institute, appeals board, priority, Luciano Marraffini
